MR1 Ligands for MAIT Cell Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying and monitoring MAIT cells are limited by the reliance on phenotypic characterization, which is prone to false positives and does not accurately distinguish MAIT cells from other T cells, and the precise identity of MR1-restricted antigens remains unknown, hindering the understanding of MAIT cell biology and therapeutic modulation.
Innovation Solution
Development of ligands that interact with MR1 to form potent MAIT-activating antigens, enabling specific identification, labeling, and modulation of MAIT cells, as well as the production of reagents for detecting and treating conditions associated with aberrant MAIT cell activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If phenotypic characterization methods are used to identify MAIT cells, then the current approach is simple and widely applicable, but the accuracy is poor leading to false positives and inability to accurately distinguish MAIT cells from other T cells
Solution Approach 1:
The patent uses MR1-ligand complexes as intermediary molecules that bridge the gap between detecting MAIT cells and their specific antigen recognition. These complexes act as mediators that enable specific identification without requiring complex multi-parameter analysis, resolving the contradiction between accuracy and complexity by providing a targeted molecular marker system
Solution Approach 2:
The patent creates artificial MR1-ligand complexes that replicate the natural antigen-MR1 interaction interface. These synthetic complexes serve as copies of the natural binding interface, allowing specific detection of MAIT cells through TCR engagement without needing to analyze complex phenotypic profiles, thus improving accuracy while maintaining method simplicity
2Adaptability or versatility
If the precise identity of MR1-restricted antigens is known, then therapeutic modulation of MAIT cells would be possible, but currently the antigens remain unknown hindering therapeutic development
Solution Approach 1:
The patent systematically varies chemical parameters of ligands bound to MR1 to identify those that specifically activate MAIT cells. By changing molecular structure, size, and chemical properties of ligands, the patent narrows down the critical binding parameters that define MAIT cell activation, thereby uncovering the functional identity of MR1-restricted antigens and enabling targeted therapeutic modulation
Solution Approach 2:
The patent extracts and isolates the critical functional information about MR1-restricted antigens by separating the essential binding features from non-essential components. Through systematic analysis of ligand structures and their biological activities, the patent extracts the minimal informative parameters that define MAIT cell activation, transforming unknown antigen identity into actionable knowledge for therapy
3Reliability
If endogenous MR1 is detected at very low levels using available monoclonal antibodies, then the conservation of MR1 across species is evident, but the surface expression is insufficient for effective MAIT cell development without transfection
Solution Approach 1:
The patent creates composite MR1-ligand complexes that combine the conserved MR1 molecule with specific ligands to enhance surface expression and functional activity. These composite structures leverage the evolutionary conservation of MR1 while adding ligand-induced stabilization and upregulation effects, thereby achieving sufficient surface expression for MAIT cell development without requiring transfection
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described ligands allow for precise detection and modulation of MAIT cells, facilitating research, diagnostics, and therapeutic interventions by accurately identifying and characterizing MAIT cells and modulating their activity, thereby addressing the limitations of existing methods.
Implementation Method 1
The MR1 protein, like MHC class I, is comprised of a heavy chain (comprised of the α1, α2 and α3 domains) non-covalently associated with a light chain (β2-microglobulin)... MAIT cells, like NKT cells, rapidly produce a broad range of cytokines upon activation
Implementation Method 2
Cells were incubated with 5-A-RU, a compound that interacts with MR1 to form potent MAIT-activating antigens... The MR1 protein presents ligands to MAIT cells through the T cell receptor
Data Source
AI summary
The present invention provides ligands which bind to MR1, some of which induce MR1 to bind to MAIT cells thereby activating or inhibiting MAIT cell activation.